{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T18:21:54Z","timestamp":1794075714154,"version":"4.8.0"},"reference-count":41,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T00:00:00Z","timestamp":1725926400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JHD"],"published-print":{"date-parts":[[2024,9,10]]},"abstract":"<jats:p>Background: The Huntington\u2019s Disease (HD) Everyday Functioning (Hi-DEF) is a new patient-reported outcome (PRO) instrument designed to measure the impact of cognitive impairment on daily functioning in the early stages of HD. Objective: To assess the measurement properties and finalize item content of the Hi-DEF. Methods: A cross-sectional, observational psychometric validation study was conducted among individuals with early stages of HD at 9 US centers of excellence. Rasch Measurement Theory (RMT) analysis of the initial draft version of the Hi-DEF (47 items) and subscales (i.e., \u2018Home\u2019, \u2018At work\u2019, \u2018Driving\u2019, and \u2018Communication\u2019) was conducted to examine measurement properties including sample-to-scale targeting, suitability of response scale (ordering of response thresholds), scale cohesiveness (item fit), local independence, and person fit. Results: 151 participants (mean age 47 years (SD 12), 59% female) were included. Seven items were removed based on dependency and item fit. The remaining 40-item version of the Hi-DEF demonstrated good measurement properties. Across the four subscales, targeting ranged from 49\u201370% (72% full scale), reliability ascertained by person separation index ranged from 0.53\u20130.87 (0.92 full scale), response scales were ordered for 25\u2013100% of items (75% full scale), 0\u201312% items displayed misfit (2% full scale), and 0\u20131% (2% full scale) item pairs displayed dependency. Conclusions: Our study supports the psychometric integrity of the Hi-DEF as a reliable and valid new PRO instrument designed to assess the impact of cognitive impairment on daily functioning in the early stages of HD. Future work will evaluate the external validity and utility in clinical trial applications.<\/jats:p>","DOI":"10.3233\/jhd-240001","type":"journal-article","created":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T10:09:33Z","timestamp":1724753373000},"page":"385-397","source":"Crossref","is-referenced-by-count":2,"title":["Rasch Measurement Theory (RMT) Analyses of the Huntington\u2019s Disease Everyday Functioning (Hi-DEF) to Evaluate Item Fit and Performance"],"prefix":"10.1177","volume":"13","author":[{"given":"Jennifer","family":"Petrillo","sequence":"first","affiliation":[{"name":"Sage Therapeutics, Inc., Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruta","family":"Sawant","sequence":"additional","affiliation":[{"name":"Sage Therapeutics, Inc., Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Elliott","sequence":"additional","affiliation":[{"name":"Modus Outcomes, a Division of THREAD, St. James Square, Cheltenham, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Cleanthous","sequence":"additional","affiliation":[{"name":"Modus Outcomes, a Division of THREAD, St. James Square, Cheltenham, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Rogers","sequence":"additional","affiliation":[{"name":"Modus Outcomes, a Division of THREAD, St. James Square, Cheltenham, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Cano","sequence":"additional","affiliation":[{"name":"Modus Outcomes, a Division of THREAD, St. James Square, Cheltenham, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Baradaran","sequence":"additional","affiliation":[{"name":"Sage Therapeutics, Inc., Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Johannesen","sequence":"additional","affiliation":[{"name":"Sage Therapeutics, Inc., Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"issue":"1","key":"10.3233\/JHD-240001_ref1","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/ene.13413","article-title":"Huntington\u2019s disease: A clinical review","volume":"25","author":"McColgan","year":"2018","journal-title":"Eur J Neurol"},{"key":"10.3233\/JHD-240001_ref2","doi-asserted-by":"crossref","unstructured":"Yohrling G , Raimundo K , Crowell V , Lovecky D , Vetter L , Seeberger L . Prevalence of Huntington\u2019s disease in the US (954). AAN Enterprises; 2020.","DOI":"10.1212\/WNL.94.15_supplement.954"},{"issue":"2","key":"10.3233\/JHD-240001_ref3","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ajhg.2015.12.018","article-title":"The HTT CAG-expansion mutation determines age at death but not disease duration in Huntington disease","volume":"98","author":"Keum","year":"2016","journal-title":"Am J Hum Genet"},{"key":"10.3233\/JHD-240001_ref4","doi-asserted-by":"crossref","unstructured":"Kwa L , Larson D , Yeh C , Bega D . Influence of age of onset on Huntington\u2019s disease phenotype (1885). AAN Enterprises; 2020.","DOI":"10.1212\/WNL.94.15_supplement.1885"},{"issue":"5","key":"10.3233\/JHD-240001_ref5","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1007\/s11910-011-0215-x","article-title":"Cognitive impairment in Huntington disease: Diagnosis and treatment","volume":"11","author":"Paulsen","year":"2011","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"3-4","key":"10.3233\/JHD-240001_ref6","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.brainresbull.2010.04.003","article-title":"Striatal and white matter predictors of estimated diagnosis for Huntington disease","volume":"82","author":"Paulsen","year":"2010","journal-title":"Brain Res Bull"},{"issue":"5","key":"10.3233\/JHD-240001_ref7","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/mds.25864","article-title":"The cognitive burden in Huntington\u2019s disease: Pathology, phenotype, and mechanisms of compensation","volume":"29","author":"Papoutsi","year":"2014","journal-title":"Mov Disord"},{"key":"10.3233\/JHD-240001_ref8","doi-asserted-by":"crossref","unstructured":"Hendel RK , Hellem MNN , Larsen IU , Vinther-Jensen T , Hjermind LE , Nielsen JE , et al. Impairments of social cognition significantly predict the progression of functional decline in Huntington\u2019s disease: A 6-year follow-up study. Appl Neuropsychol Adult. 2022. https:\/\/doi.org\/10.1080\/23279095.2022.2073824","DOI":"10.1080\/23279095.2022.2073824"},{"key":"10.3233\/JHD-240001_ref9","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s13023-014-0114-8","article-title":"A clinical classification acknowledging neuropsychiatric and cognitive impairment in Huntington\u2019s disease","volume":"9","author":"Vinther-Jensen","year":"2014","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.3233\/JHD-240001_ref10","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1146\/annurev-psych-113011-143750","article-title":"Executive functions","volume":"64","author":"Diamond","year":"2013","journal-title":"Ann Rev Psychol"},{"issue":"3","key":"10.3233\/JHD-240001_ref11","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s11065-007-9040-z","article-title":"The elusive nature of executive functions: A review of our current understanding","volume":"17","author":"Jurado","year":"2007","journal-title":"Neuropsychol Rev"},{"key":"10.3233\/JHD-240001_ref12","first-page":"646","article-title":"Executive dysfunction","volume":"21","author":"Rabinovici","year":"2015","journal-title":"Continuum (Minneap Minn)"},{"issue":"4","key":"10.3233\/JHD-240001_ref13","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1017\/S1355617722000364","article-title":"On the association between apathy and deficits of social cognition and executive functions in Huntington\u2019s disease","volume":"29","author":"Hendel","year":"2022","journal-title":"J Int Neuropsychol Soc"},{"key":"10.3233\/JHD-240001_ref14","doi-asserted-by":"crossref","unstructured":"Billet J , Levine A , Johannesen J , Lovell T , Rams A , Gusse E , et al. Patient experiences in early Huntington\u2019s disease-qualitative research to inform development of a patient-reported instrument of everyday functioning (P3-11.003). AAN Enterprises; 2022.","DOI":"10.1212\/WNL.98.18_supplement.2666"},{"issue":"6","key":"10.3233\/JHD-240001_ref15","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.knee.2015.04.002","article-title":"Patient-reported outcome measures versus inertial performance-based outcome measures: A prospective study in patients undergoing primary total knee arthroplasty","volume":"22","author":"Bolink","year":"2015","journal-title":"Knee"},{"key":"10.3233\/JHD-240001_ref16","doi-asserted-by":"crossref","first-page":"223","DOI":"10.5334\/tohm.177","article-title":"HD-PRO-TRIAD\u2122 validation: A patient-reported instrument for the symptom triad of Huntington\u2019s disease","volume":"4","author":"Carlozzi","year":"2014","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"issue":"10","key":"10.3233\/JHD-240001_ref17","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1007\/s11136-016-1386-3","article-title":"HDQLIFE: Development and assessment of health-related quality of life in Huntington disease (HD)","volume":"25","author":"Carlozzi","year":"2016","journal-title":"Qual Life Res"},{"issue":"suppl 2","key":"10.3233\/JHD-240001_ref18","first-page":"Abstract 870","article-title":"Functional Rating Scale 2.0 (FuRST2.0), a patient reported outcome measure for Huntington\u2019s disease: The importance of the patient voice in scale development [abstract]","volume":"37","author":"Fuller","year":"2022","journal-title":"Mov Disord"},{"issue":"1","key":"10.3233\/JHD-240001_ref19","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jval.2014.10.005","article-title":"Using classical test theory, item response theory, and Rasch measurement theory to evaluate patient-reported outcome measures: A comparison of worked examples","volume":"18","author":"Petrillo","year":"2015","journal-title":"Value Health"},{"key":"10.3233\/JHD-240001_ref20","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s41687-019-0130-5","article-title":"State of the psychometric methods: Patient-reported outcome measure development and refinement using item response theory","volume":"3","author":"Stover","year":"2019","journal-title":"J Patient Rep Outcomes"},{"key":"10.3233\/JHD-240001_ref21","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s40271-013-0041-0","article-title":"An introduction to item response theory for patient-reported outcome measurement","volume":"7","author":"Nguyen","year":"2014","journal-title":"Patient"},{"key":"10.3233\/JHD-240001_ref22","doi-asserted-by":"crossref","unstructured":"Billet J , Levine A , Johannesen J , Sawant R , Lovell T , Rams A , et al. Psychometric validation of Huntington\u2019s Disease Everyday Functioning (Hi-DEF) Scale \u2013 study design and sample characteristics (P3-11.005). Neurology. 2022;98(18_supplement).","DOI":"10.1212\/WNL.98.18_supplement.3006"},{"issue":"1","key":"10.3233\/JHD-240001_ref23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/WNL.29.1.1","article-title":"Huntington disease: Clinical care and evaluation","volume":"29","author":"Shoulson","year":"1979","journal-title":"Neurology"},{"key":"10.3233\/JHD-240001_ref25","unstructured":"Wright B , Stone M . Best test design: Rasch measurement. Chicago: MESA Press; 1979."},{"issue":"5","key":"10.3233\/JHD-240001_ref26","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1586\/erp.11.59","article-title":"Rating scales and Rasch measurement","volume":"11","author":"Andrich","year":"2011","journal-title":"Expert Rev Pharmacoeconomics Outcomes Res"},{"issue":"12","key":"10.3233\/JHD-240001_ref27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta13120","article-title":"Improving the evaluation of therapeutic interventions in multiples sclerosis: The role of new psychometric methods","volume":"13","author":"Hobart","year":"2009","journal-title":"Health Technol Assess"},{"key":"10.3233\/JHD-240001_ref28","doi-asserted-by":"crossref","unstructured":"Petrillo J , Cadavid D , Castrillo-Viguera C , Cleanthous S , Pompilus F , Strzok S , et al. Expanding our understanding of daily life activity impact in patients with multiple sclerosis. 7th Joint ECTRIMS-ACTRIMS Meeting; Paris, France, 2017.","DOI":"10.26226\/morressier.59a3edacd462b8028d8959d7"},{"issue":"12","key":"10.3233\/JHD-240001_ref32","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/jnnp.2009.204008","article-title":"The ADAS-cog in Alzheimer\u2019s disease clinical trials: Psychometric evaluation of the sum and its parts","volume":"81","author":"Cano","year":"2010","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"10.3233\/JHD-240001_ref33","first-page":"S4","article-title":"Putting the Alzheimer\u2019s cognitive test to the test I: Traditional psychometric methods","volume":"9","author":"Hobart","year":"2013","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JHD-240001_ref34","first-page":"59","volume-title":"Applications of latent trait and latent class models in the social sciences","author":"Andrich","year":"1997"},{"key":"10.3233\/JHD-240001_ref35","unstructured":"Wright BD , Masters GN . Rating scale analysis: MESA press; 1982."},{"key":"10.3233\/JHD-240001_ref36","doi-asserted-by":"crossref","first-page":"I7","DOI":"10.1097\/01.mlr.0000103528.48582.7c","article-title":"Controversy and the Rasch model: A characteristic of incompatible paradigms?","volume":"42","author":"Andrich","year":"2004","journal-title":"Med Care"},{"issue":"4","key":"10.3233\/JHD-240001_ref37","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/BF01593882","article-title":"Individual-patient monitoring in clinical practice: Are available health status surveys adequate?","volume":"4","author":"McHorney","year":"1995","journal-title":"Qual Life Res"},{"issue":"3","key":"10.3233\/JHD-240001_ref38","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1037\/1040-3590.7.3.286","article-title":"Factor analysis in the development and refinement of clinical assessment instruments","volume":"7","author":"Floyd","year":"1995","journal-title":"Psychol Assess"},{"issue":"5","key":"10.3233\/JHD-240001_ref39","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1177\/1352458517690821","article-title":"Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis","volume":"23","author":"Benedict","year":"2017","journal-title":"Mult Scler"},{"key":"10.3233\/JHD-240001_ref40","doi-asserted-by":"crossref","first-page":"224","DOI":"10.5334\/tohm.178","article-title":"Identifying motor, emotional\u2013behavioral, and cognitive deficits that comprise the triad of HD symptoms from patient, caregiver, and provider perspectives","volume":"4","author":"Victorson","year":"2014","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"issue":"2","key":"10.3233\/JHD-240001_ref41","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1399-0004.2011.01823.x","article-title":"The Huntington\u2019s Disease health-related Quality of Life questionnaire (HDQoL): A disease-specific measure of health-related quality of life","volume":"81","author":"Hocaoglu","year":"2012","journal-title":"Clin Genet"},{"issue":"4","key":"10.3233\/JHD-240001_ref42","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/YIC.0b013e3283534fa9","article-title":"Validation of the first quality-of-life measurement for patients with Huntington\u2019s disease: The Huntington Quality of Life Instrument","volume":"27","author":"Clay","year":"2012","journal-title":"Int Clin Psychopharmacol"},{"issue":"1","key":"10.3233\/JHD-240001_ref43","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s13023-017-0718-x","article-title":"Measuring what matters to rare disease patients\u2013reflections on the work by the IRDiRC taskforce on patient-centered outcome measures","volume":"12","author":"Morel","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"10.3233\/JHD-240001_ref44","doi-asserted-by":"crossref","first-page":"697234","DOI":"10.3389\/fnagi.2021.697234","article-title":"Awareness of cognitive decline in patients with Alzheimer\u2019s disease: A systematic review and meta-analysis","volume":"13","author":"Cacciamani","year":"2021","journal-title":"Front Aging Neurosci"},{"key":"10.3233\/JHD-240001_ref45","unstructured":"Petrillo J , Elliott E , Rogers R , Cleanthous S , Sawant R , Mazerolle F , et al. Reliability and Construct Validity of the Huntington\u2019s Disease (HD) Everyday Functioning (Hi-DEF) Using Classical Test Theory Approach. Abstracts of the 29th Annual Meeting of the Huntington Study Group; November 3\u20135, 2022, Tampa, Florida."}],"container-title":["Journal of Huntington's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JHD-240001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:56:26Z","timestamp":1777452986000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JHD-240001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,10]]},"references-count":41,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.3233\/jhd-240001","relation":{},"ISSN":["1879-6397","1879-6400"],"issn-type":[{"value":"1879-6397","type":"print"},{"value":"1879-6400","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,10]]}}}